Long-term follow-up of allogeneic bone marrow transplantation for patients with chronic phase chronic myeloid leukemia prepared with a regimen consisting of cyclophosphamide, cytarabine and single-dose total body irradiation conditioning

Bone Marrow Transplantation

Volumn 40, Issue 5, 2007, Pages 423-430

  Zaretsky, Y ^a   Rifkind, J ^a   Lockwood, G ^a   Tsang, R ^a   Kiss, T ^a   Hasegawa, W ^a   Fyles, G ^a   Tejpar, I ^a   Loach, D ^a   Minden, M ^a   Messner, H ^a   Lipton, J H ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AZATHIOPRINE; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; GANCICLOVIR; IMATINIB; IMMUNOSUPPRESSIVE AGENT; INTERFERON; METHOTREXATE; METHYLPREDNISOLONE; PENTAMIDINE; PREDNISONE; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLERGY; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BACTERIAL INFECTION; BRONCHIOLITIS OBLITERANS; CATARACT; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; CONTINUOUS INFUSION; CONTROLLED STUDY; CYTOGENETICS; CYTOMEGALOVIRUS INFECTION; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG WITHDRAWAL; ENGRAFTMENT; FEMALE; FOLLOW UP; GRAFT FAILURE; HERPES SIMPLEX; HUMAN; INTERSTITIAL PNEUMONIA; LEUKEMIA RELAPSE; LEUKOCYTE TRANSFUSION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OVERALL SURVIVAL; PNEUMOCYSTOSIS; PRIORITY JOURNAL; TREATMENT OUTCOME; VEIN OCCLUSION; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; BONE MARROW TRANSPLANTATION; CYCLOPHOSPHAMIDE; CYTARABINE; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HUMANS; LEUKEMIA, MYELOID, CHRONIC-PHASE; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; WHOLE-BODY IRRADIATION;

EID: 34548086578     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705755     Document Type: Article

References (36)

1. Sampath S, Schultheiss TE, Wong J. Dose response and factors related to interstitial pneumonitis after bone marrow transplant. Int J Radiat Oncol Biol Phys 2005; 3: 876-884.
2. Keane TJ, Van Dyk J, Rider WD. Idiopathic interstitial pneumonia following bone marrow transplantation: The relationship with total body irradiation. Int J Radiat Oncol Biol Phys 1981; 7: 1365-1370.
3. Barrett A. Total body irradiation (TBI) before bone marrow transplantation in leukaemia: A co-operative study from the European Group for Bone Marrow Transplantation. Br J Radiol 1982; 55: 562-567.
4. Deeg HJ, Sullivan KM, Buckner CD, Storb R, Appelbaum FR, Clift, RA et al. Marrow transplantation for acute nonlymphoblastic leukemia in first remission: Toxicity and long-term follow-up of patients conditioned with single dose or fractionated total body irradiation. Bone Marrow Transplant 1986; 1: 151-157.
5. Dinsmore R, Kirkpatrick D, Flomenberg N, Gulati S, Kapoor N, Brochstein J et al. Allogeneic bone marrow transplantation for patients with acute nonlymphocytic leukemia. Blood 1984; 63: 649-656.
6. Kim TH, Kersey J, Sewchand W, Nesbit ME, Krivit W, Levitt SH. Total-body irradiation with a high-dose-rate linear accelerator for bone-marrow transplantation in aplastic anemia and neoplastic disease. Radiology 1977; 122: 523-525.
7. Lichter AS, Tutschka PJ, Wharam MD, Elfenbein GJ, Sensenbrenner LL, Saral R et al. The use of fractionated radiotherapy as preparation for allogeneic bone marrow transplantation. Transplant Proc 1979; 11: 1492-1494.
8. Thomas ED, Clift RA, Buckner CD, Marrow transplantation for patients with acute nonlymphoblastic leukemia who achieve a first remission. Cancer Treat Rep 1982; 66: 1463-1466
9. Storb R, Raff RF, Appelbaum FR, Graham TC, Schuening FG, Sale G et al. Comparison of fractionated to single-dose total body irradiation in conditioning canine littermates for DLA-identical marrow grafts. Blood 1989; 74: 1139-1143.
10. Storb R, Raff RF, Graham T, Appelbaum FR, Deeg HJ, Schuening FG et al. Marrow toxicity of fractionated vs single dose total body irradiation is identical in a canine model. Int J Radiat Oncol Biol Phys 1993; 26: 275-283.
11. Storb R, Raff RF, Appelbaum FR, Deeg HJ, Graham TC, Schuening FG et al. Fractionated versus single-dose total body irradiation at low and high dose rates to condition canine littermates for DLA-identical marrow grafts. Blood 1994; 83: 3384-3389.
12. Fyles GM, Messner HA, Lockwood G, Curtis JE, Rider W, Minden MD, et al. Long-term results of bone marrow transplantation for patients with AML, ALL and CML prepared with single dose total body irradiation of 500 cGy delivered with a high dose rate. Bone Marrow Transplant 1991; 8: 453-463.
13. Curtis JE, Messner HA. Bone marrow transplantation for leukemia and aplastic anemia: Management of ABO incompatibility Can Med Assoc J 1982; 126: 649-655.
14. Fryer CJ, Fitzpatrick PJ, Rider WD. Poon P. Radiation pneumonitis: experience following a large single dose of radiation. Int J Radiat Oncol Biol Phys 1978; 4: 931-936.
15. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295-304.
16. Sullivan KM. Acute and chronic graft-versus-host disease in man. Int J Cell Cloning 1986; 4 (Suppl 1): 42-93.
17. Thomas ED, LeBlond R, Graham T, Storb R. Marrow infusions in dogs given midlethal or lethal irradiation. Radiat Res 1970; 41: 113-124.
18. Long GD, Amylon MD, Stockerl-Goldstein KE, Negrin RS, Chao NJ, Hu WW et al. Fractionated total-body irradiation etoposide and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies. Biol Blood Marrow Transplant 1997; 3: 324-330.
19. Or R, Shapira MY, Resnick I, Amar A, Ackerstein A, Samuel S et al. Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood 2003; 101: 441-445.
20. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763.
21. Giralt S, Thall PF, Khouri I, Wang X, Braunschweig I, Ippolitti C et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001; 97: 631-637.
22. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390-3400.
23. Michallet M, Bilger K, Garban F, Attal M, Huyn A, Blaise D et al. Allogeneic hematopoietic stem-cell transplantation after nonmyeloablative preparative regimens: Impact of pretransplantation and posttransplantation factors on outcome. J Clin Oncol 2001; 19 3340-3349.
24. Maris MB, Niederwieser D, Sandmaier BM, Storer B, Stuart M, Maloney D et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood 2003; 102: 2021-2030.
25. Gratwohl A, Hermans J, Niederwieser D, Frassoni F, Arcese W, Gahrton G et al. Bone marrow transplantation for chronic myeloid leukemia: long-term results. Chronic Leukemia Working Party of the European Group for Bone Marrow Transplantation. Bone Marrow Transplant 1993; 12: 509-516.
26. van Rhee F, Szydlo RM, Hermans J, Devergie A, Frassoni F, Arcese W et al. Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: A report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1997; 20: 553-560.
27. Blum W, Brown R, Lin HS, Zehnbauer B, Khoury H, Goodnough LT et al. Low-dose (550 cGy) single-exposure total body irradiation and cyclophosphamide: Consistent durable engraftment of related-donor peripheral blood stem cells with low treatment-related mortality and fatal organ toxicity. Biol Blood Marrow Transplant 2002; 8: 608-618.
28. Morton AJ, Gooley T, Hansen JA, Appelbaum FR, Bruemmer B, Bjerke JW et al. Association between pretransplant interferon-alpha and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia in chronic phase. Blood 1998; 92: 394-401.
29. Beelen DW, Graeven U, Elmaagacli AH, Niederle N, Kloke O, Opalka B et al. Prolonged administration of interferon-alpha in patients with chronic-phase Philadelphia chromosomepositive chronic myelogenous leukemia before allogeneic bone marrow transplantation may adversely affect transplant outcome. Blood 1995; 85: 2981-2990.
30. Giralt S, Szydlo R, Goldman JM, Veum-Stone J, Biggs JC, Herzig RH et al. Effect of short-term interferon therapy on the outcome of subsequent HLA-identical sibling bone marrow transplantation for chronic myelogenous leukemia: An analysis from the international bone marrow transplant registry. Blood 2000; 95: 410-415.
31. Giralt SA, Kantarjian HM, Talpaz M, Rios MB, Del Giglio A, Andersson BS et al. Effect of prior interferon alfa therapy on the outcome of allogeneic bone marrow transplantation for chronic myelogenous leukemia. J Clin Oncol 1993; 11: 1055-1061.
32. Lee SJ, Klein JP, Anasetti C, Antin JH, Loberiza FR, Bolwell BJ et al. The effect of pretransplant interferon therapy on the outcome of unrelated donor hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in first chronic phase. Blood 2001; 98: 3205-3211.
33. Pigneux A, Tanguy ML, Michallet M, Jouet JP, Kuentz M, Vernant JP et al. Prior treatment with alpha interferon does not adversely affect the outcome of allogeneic transplantation for chronic myeloid leukaemia. Br J Haematol 2002; 116: 193-201.
34. Tomas JF, Lopez-Lorenzo JL, Requena MJ, Aguilar R, Steegmann JL, Camara R et al. Absence of in uence of prior treatment with interferon on the outcome of allogeneic bone marrow transplantation for chronic myeloid leukemia. Bone Marrow Transplant 1998; 22: 47-51.
35. Kiss TL, Abdolell M, Jamal N, Minden MD, Lipton JH, Messner HA. Long term medical outcomes and quality of life assessment of patients with chronic myeloid leukemia followed at least 10 years after allogeneic bone marrow transplant. J Clin Oncol 2002; 20: 2334-2343.
36. Khoury H, Adkins D, Brown R, Pence H, Vij, Goodnough LT et al. Low incidence of transplantation-related acute complications in patients with chronic myeloid leukemia undergoing allogeneic stem cell transplantation with a lowdose (550 cGy) total body irradiation conditioning regimen. Biol Blood Marrow Transplant 2001; 7: 352-358.